The global porphyria market is expected to register a significant revenue CAGR during the forecast period. Leading Biotechnology companies’ increased focus on developing drugs to treat porphyria, as well as government funding and initiatives to support and scale up research and development operations for treating porphyria, are the main factors driving the market’s revenue growth.
